Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/613657


Czech Republic Pharmaceuticals and Healthcare Report Q2 2008


Description: The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republics pharmaceuticals and healthcare industry.

Growth in the Czech drug market is beginning to fall away but should remain impressive over the forecast period, comfortably outpacing the more mature markets in Western Europe. In 2007, drug expenditure expanded by 7.5% to reach US$3.11bn but by 2012 annual growth is expected to have slipped under 7%, while the total market value should be US$4.33bn. Growth in the OTC sector should be marginally higher than for prescription drugs, while generics should expand at a quicker rate than patented drugs, driven by the government’s new cost containment measures.

In January 2008, the new prescription charges, whereby adults pay a mandatory fee of CZK30 (US$1.46) for each medicine pack, came into force. The charge is designed to discourage patients stockpiling medicines, which had been a common practice and costs the state billions of korunas a year. However, pharmacies claim that they are not profiting from the reforms, which is putting the system in jeopardy. Although they are allowed to keep the prescription fees, they also have to offer significant discounts in order to take the burden of cost off the consumer.

Meanwhile, Health Minister Thomas Julínek has claimed that an extra CZK13bn (US$723mn) will be spent on medical treatment in 2008 as a result of improved efficiency in the insurance sector and the introduction of the co-payments scheme, which also extends to doctors and hospital visits. When Julínek became health minister in September 2006, he placed great emphasis on reform in the insurance sector.

According to Julínek, health insurers are now learning how to purchase better care for patients at lower costs. The savings are subsequently being used to improve quality of care or increase patient volume.

In terms of the Business Environment Rankings, little has changed in the Czech Republic, although BMI has marginally upgraded the score for country risk. However, excessive bureaucracy, as is common in many ex-Soviet bloc states, continues to be a real problem. The Czech Republic remains in second place in the regional rankings, although the fiscally conservative administration is beginning to restrict health spending as it seeks to reduce the budget deficit and smooth the country’s way into the euro.


Contents: Executive Summary
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Pharmaceutical Business Environment Ratings Limits To Potential Returns
Risks To Realisation Of Returns
Czech Republic - Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Pharmacy Sector
Hospital Sector
Healthcare Sector
Research And Development Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2005-2012
Key Growth Factors - Industry
Table: Czech Republic’s Health Expenditure Forecast Indicators
Key Growth Factors - Macroeconomic
Table: Czech Republic - Economic Activity
Patented Market Forecasts
Table: Patented Drugs Market Forecast Indicators (US$mn unless otherwise stated)
OTC Market Forecasts
Table: OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecasts
Table: Czech Republic’s Generics Market Forecast Indicators
Export/Import Forecasts
Table: Czech Republic Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To our Forecast Scenario
Competitive Landscape
Wholesale
Retail
Company Monitor

Multinational Companies
- AstraZeneca
- Bristol-Myers Squibb
- Sanofi-Aventis
- Walmark

Local Company
- Zentiva (incorporating Sicomed)

Our Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources



Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Sanofi-Aventis - Walmark - Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/613657

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 28/11/2009 05:17:09
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q2 2008
Web Address:
http://www.researchandmarkets.com/reports/613657
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 28/11/2009 05:17:09

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)